Drug Profile
Autologous diabetes stem cell therapy - Cellonis Biotechnologies
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cellonis Biotechnologies
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus in China (Parenteral)
- 24 Jun 2010 Phase-I clinical trials in Diabetes mellitus in China (Parenteral)